uniQure N.V.
0EE0.L
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.57B
Close$
$-8.51
140.3% downside
Current Fair Value
140.3% downsideOvervalued by 140.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.57 Billion |
|---|---|
| Enterprise Value | $1.22 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.46 |
| Beta | 0.94 |
| Outstanding Shares | 66,243,879 |
Return
| Return on Equity | -77.83% |
|---|---|
| Return on Assets | -25.60% |
| Return on Invested Capital | -29.63% |
Valuation & Multiples
| P/E Ratio | -5.59 |
|---|---|
| PEG | -4.87 |
| Price to Sales | - |
| Price to Book Ratio | 5.28 |
| Enterprise Value to Revenue | 65.17 |
| Enterprise Value to EBIT | -4.55 |
| Enterprise Value to Net Income | -5 |
| Total Debt to Enterprise | 0.05 |
| Debt to Equity | 0.19 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
July 29, 2026
EPS Estimate
$-0.82
Average shareholder expectationRevenue Estimate
$5.45 M
Average shareholder expectationNext Earnings Call
Expected Date
November 9, 2026
EPS Estimate
$-0.92
Average shareholder expectationRevenue Estimate
$6.21 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About uniQure N.V.
221 employees
CEO: Matthew C. Kapusta uniQure is delivering on the promise of gene therapy - single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary gene therapies to tr...